Mix-and-match approach boosts immune response of AstraZeneca shot, study finds

Record ID: 1623811

  • Title: Mix-and-match approach boosts immune response of AstraZeneca shot, study finds
  • Date: 28th June 2021
  • Summary: OXFORD, ENGLAND, UNITED KINGDOM (JUNE 28, 2021) (REUTERS VIA ZOOM) SOUNDBITE (English) ASSOCIATE PROFESSOR IN PAEDIATRICS AND VACCINOLOGY, MATTHEW SNAPE, SAYING: “I think these mix-and-match type studies are really important when it comes to thinking about how these vaccines are going to be used globally, and other studies are looking at other vaccines including the Chinese vaccine, the SputnikV vaccines, because these are the vaccines that might be used more in low and middle income countries, where the vaccine supply might not be as predictable and so you are almost forced or by necessity using mix and match schedules and so the more studies that look at the interaction between how these vaccines and how the vaccine combinations work well, which ones you might not want to use, I think it’s really important field of research so that we get a better idea of how to use them.“
  • Embargoed: 12th July 2021 18:08
  • Keywords: AstraZenica Jenner Institute Oxford Pfizer vaccine vaccine cocktail
  • Location: OXFORD AND MACCLESFIELD, ENGLAND, UNITED KINGDOM, BRAINE-LE-COMTE AND PUURS, BELGIUM,
  • City: OXFORD AND MACCLESFIELD, ENGLAND, UNITED KINGDOM, BRAINE-LE-COMTE AND PUURS, BELGIUM,
  • Country: United Kingdom
  • Topics: Europe,Health/Medicine
  • Reuters ID: LVA004EJBGRWN
  • Aspect Ratio: 16:9
  • Story Text:A mixed schedule of vaccines where a shot of Pfizer's COVID-19 vaccine is given four weeks after an AstraZeneca shot will produce better immune responses than giving another dose of AstraZeneca, an Oxford study said on Monday (June 28).
    The study, called Com-COV, compared mixed two-dose schedules of Pfizer and AstraZeneca vaccines, and found that in any combination, they produced high concentrations of antibodies against the coronavirus spike protein.
    The data provides support for the decision of some European countries that have started offering alternatives to AstraZeneca as a second shot after the vaccine was linked to rare blood clots.
    Matthew Snape, the Oxford professor behind the trial, said that the findings could be used to give flexibility to vaccine rollouts, but was not large enough to recommend a broader shift away from clinically approved schedules on its own.
    The highest antibody response was seen in people receiving two doses of Pfizer vaccine, with both mixed schedules producing better responses than two doses of AstraZeneca vaccine.
    An AstraZeneca shot followed by Pfizer produced the best T-cell responses, and also a higher antibody response than Pfizer followed by AstraZeneca.
    The results were for combinations of vaccines given at four week intervals to 830 participants.
    Com-COV is also looking at mixed schedules over a 12-week interval, and Snape noted that AstraZeneca's shot was known to produce a better immune response with a longer interval between doses.
    (Production : Natalie Thomas)
  • Copyright Holder: REUTERS
  • Copyright Notice: (c) Copyright Thomson Reuters 2021. Open For Restrictions - http://about.reuters.com/fulllegal.asp
  • Usage Terms/Restrictions: None
Register